:format(webp))
With autologous and allogeneic therapies requiring precise temperature controls and coordination, traditional logistics frameworks are no longer sufficient to guarantee safety.
Discover how QuickSTAT’s specialised CGT solutions provide the infrastructure, end-to-end visibility, and meticulous handling required to safeguard advanced therapeutics. Protect the integrity of your therapy at every crucial milestone from bench to bedside.
How QuickSTAT uses specialised cryogenic (liquid nitrogen/LN2), ultra-frozen, and controlled room temperature (CRT) shipping solutions to maintain strict thermal boundaries during transit.
The rigorous monitoring and tracking protocols implemented to manage patient-specific shipments, eliminating the risk of product mix-ups.
How our dedicated CGT control towers monitor flights, weather disruptions, and customs clearance procedures 24/7/365 to intervene before delays occur.
A look at QuickSTAT’s expanding network of GDP-compliant facilities that support advanced therapies from early-phase clinical trials to commercial launch.
Loading iFrame
Press play to get started.
In autologous CGT trials, a single patient is often both the source and the recipient of the medicine. A logistical failure doesn't just damage product—it can directly deny a patient their treatment window.
Living cells and genetic materials are highly fragile and often impossible to remanufacture or replace; ensuring absolute cold chain integrity is paramount.
Partnering with a specialized CGT expert ensures total alignment with global regulatory expectations, protecting your data integrity and trial validation.